PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION BY INJECTION

Abstract

A pharmaceutical composition for administration by injection, comprising a mixture of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B′ independently of one another are a halogen atom or a hydroxy group or are an -0-C(O)—R or -0-C(O)—R′ group wherein R and R′ independently of one another are a hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group, which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X′ independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X′ together form a dicarboxylate group containing 2 to 20 carbon atoms, and of at least one cyclodextrin and/or at least one cyclodextrin derivative, and optionally of at least one pharmaceutically acceptable excipient.

Description

FIELD OF THE INVENTION

The invention relates to a pharmaceutical composition for administration by injections, containing as active substance a complex of tetravalent platinum of limited solubility in water and enabling systemic as well as local application of the said complex to the organism.

BACKGROUND OF THE INVENTION

Platinum complexes are generally known as effective substances having a broad spectrum of antitumor effect and they are thus utilized in the treatment of many of tumor diseases. So far, the therapeutic practice has used only complexes of bivalent platinum, especially cisplatinum, carboplatinum or oxaliplatinum. It has been found that some complexes of tetravalent platinum exhibit the same, or even higher, antitumor effect in comparison with that of bivalent platinum complexes and, moreover, they are less toxic. Specific complexes of tetravalent platinum were disclosed as novel chemical compounds in EP 0 328 274, EP 0 423 707 and PCT/CZ99/00015.

However, complexes of tetravalent platinum in general are very poorly soluble in water, which represents a serious problem in cases where it is necessary to prepare their liquid, especially injection, drug form. Whereas the solubility of cisplatinum, carboplatinum and oxaliplatinum in water is 0.3 mg/ml, 17 mg/ml and 8 mg/ml, respectively, the solubility of the tetravalent platinum complex LA-12 in water is only 0.03 mg/ml. The solubility of tetravalent platinum complexes in water can be increased according to PCT/CZ99/00015 which patent document describes the preparation of drug forms of specific tetravalent platinum complexes in the form of their inclusion complexes with cyclodextrins. According to the mentioned document, these inclusion complexes are obtained by reaction of cyclodextrins with complexes of tetravalent platinum in an organic solvent followed by freeze-drying, and are used for oral administration. However, disadvantage of this approach is that the amount of cyclodextrin used limits significantly the content of the tetravalent platinum complex present in the oral drug form. Thus, the obtained oral drug form is relatively voluminous and is difficult to swallow which precludes oral administration of greater amounts of tetravalent platinum complexes in a single dose. This situation could be solved by application of a relatively well water-soluble inclusion complex of cyclodextrin with tetravalent platinum complex in the form of injection. This, however, considerably complicates the relatively complicated and expensive preparation of the inclusion complex of cyclodextrin with the tetravalent platinum complex which so far requires the presence of an organic solvent.

Therefore, the aim of the invention is to find a simpler method of preparation of inclusion complexes of cyclodextrins with tetravalent platinum complexes and to provide a pharmaceutical composition comprising the thus-prepared inclusion complex and being applicable in the injection form.

Surprisingly, it has been found that inclusion complexes of specific tetravalent platinum complexes with cyclodextrins can be simply prepared solely in an aqueous medium, which represents a significant simplification not only of their preparation but also of the preparation of injectable pharmaceutical composition.

SUMMARY OF THE INVENTION

The invention relates to a pharmaceutical composition for administration by injection, characterized in that it consists of a mixture of a platinum complex of general formula I

wherein

• • A and A′ independently of one another are an NH₃ group or an amino or diamino group containing 1 to 18 carbon atoms,
  • B and B′ independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or —O—C(O)—R′ group wherein R and R′ independently of one another are hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group, which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups,
  • X and X′ independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X′ together form a dicarboxylate group containing 2 to 20 carbon atoms,and of at least one cyclodextrin and/or at least one cyclodextrin derivative,and optionally of at least one pharmaceutically acceptable excipient.

The pharmaceutical composition according to the invention is advantageously prepared in the form of an aqueous solution formed by addition of an aqueous medium to at least one cyclodextrin and/or at least one cyclodextrin derivative and subsequent addition of platinum complex of general formula I to the thus-obtained solution of at least one cyclodextrin and/or at least one cyclodextrin derivative in an aqueous medium; or by addition of an aqueous medium to a mixture of platinum derivative of the general formula I with at least one cyclodextrin and/or at least one cyclodextrin derivative; or by addition of at least one cyclodextrin and/or at least one cyclodextrin derivative to a suspension of platinum derivative of general formula I in an aqueous medium.

The pharmaceutical composition according to the invention may exist advantageously in a lyophilized or spray-dried form obtained by lyophilization or spray drying of the above mentioned aqueous solution.

The pharmaceutical composition according to the invention may exist advantageously in the form of a solution of the above mentioned lyophilized or spray-dried form in an aqueous medium.

The pharmaceutical composition according to the invention advantageously contains at least one cyclodextrin and/or at least one cyclodextrin derivative and a platinum complex of general formula I in a weight ratio 0.1:1 to 1:10, preferably 1:1 to 1:8.

Preferably, the aqueous medium is water for injections or an aqueous apyrogenic and sterile isotonic acetate, citrate or phosphate buffer, pH 4 to 8, preferably 4.

Within the framework of the invention, the term “aqueous medium” denotes water for injections or solutions of excipients in it, as accepted for intravenous application according to Pharmacopoeia. Preferred aqueous medium in a pharmaceutical composition according to the invention may be water or an aqueous buffer pH 4 to 8, such as a citrate or an acetate buffer. The invention thus provides pharmaceutical compositions for administration by injection in the following forms:

• a) dry injection form, comprising a mixture of at least one cyclodextrin and/or at least one cyclodextrin derivative and optionally at least one pharmaceutically acceptable excipient, and which is ready for application upon addition of an aqueous medium;
• b) liquid injection form which is ready for application and which is obtained either by addition of an aqueous medium to the dry injection form a), or by addition of an aqueous medium to at least one cyclodextrin and/or at least one cyclodextrin derivative and subsequent addition of platinum complex of general formula I to the obtained solution of at least one cyclodextrin and/or at least one cyclodextrin derivative in an aqueous medium, or by addition of at least one cyclodextrin and/or at least one cyclodextrin derivative to a suspension of platinum complex of general formula I in an aqueous medium;
• c) dry injection form which is obtained by lyophilization or spray-drying of the liquid injection form b), and which is ready for application upon addition of an aqueous medium;
• d) liquid injection form which is ready for application and which is obtained by addition of an aqueous medium to the dry injection form c).

In case that pharmaceutically acceptable excipients are used in the pharmaceutical composition and such excipients are not already present in the dry injection form a), these excipients may be added at any stage of preparation of the above mentioned forms b) to d). Such pharmaceutically acceptable excipients may be those that are commonly used in the preparation of injectable drug forms, e.g. isotonizing additives such as sodium chloride, or common antimicrobial additives such as e.g. benzoic acid derivatives (methyl- and propyl parabenes).

As cyclodextrins and derivatives thereof may be used preferably alfa-, beta- and gamma-cyclodextrins and their alkylated derivatives, such as particularly hydroxypropyl beta-cyclodextrin or hydroxypropyl methyl beta-cyclodextrin. In the inclusion complex, the tetravalent platinum complex is locked in the form of a partial or complete complex and such inclusion complex is practically indefinitely soluble in water. In this way, it is possible to prepare a solution of inclusion complex which is then sterilized by membrane filtration and is subsequently lyophilized or spray-dried, or simply to mix under aseptic conditions the platinum complex of general formula I and cyclodextrin and/or its derivative and to prepare the inclusion complex “in situ” only during the preparation of the liquid injection form. The pharmaceutical composition for administration by injection is advantageously employed in the form of infusion. In each individual case, the resulting concentration and volume of such pharmaceutical composition intended for administration is determined by the attending physician.

In the following part the invention will be explained in more detail using specific examples of execution which are of illustrative value only and do not limit in any way the scope of the invention that is unequivocally defined by the appending Claims.

In these examples, as a specific representative of platinum complex of general formula I serves the (OC-6-43)-bis(acetato)-(1-adamantylamine)-ammine-dichloroplatinum(IV) complex of code name LA-12 and of formula II:

In the Examples, this specific platinum complex is denoted by its code name.

EXAMPLES

Example 1

Preparation of Dry Injection Form of Platinum Complex LA-12

Platinum complex LA-12 (1 part by weight) is mixed aseptically with beta-cyclodextrin of high purity (HP-beta-cyclodextrin; 3 parts by weight). The obtained mixture is then aseptically filled into sterile depyrogenized vials in a laminar flow box of A class purity.

Example 2

Preparation of Lyophilized Injection Form of Platinum Complex LA-12

HP-beta-Cyclodextrin (3 parts by weight) is dissolved in 40 parts by weight of water for injections whereupon platinum complex LA-12 (1 part by weight) is gradually added to this solution under constant stirring. Stirring is continued until the formed inclusion complex completely dissolves. Then the solution is sterilized by membrane filtration (membrane pore size 0.22 μm), filled into vials and subjected to lyophilization.

Example 3

Preparation of Dry Injection Form of Platinum Complex LA-12

HP-beta-Cyclodextrin (3 parts by weight) is dissolved in water for injections (40 parts by weight) whereupon platinum complex LA-12 (1 part by weight) is gradually added to this solution under constant stirring. Stirring is continued until the formed inclusion complex completely dissolves. Then the solution is sterilized by membrane filtration (membrane pore size 0.22 μm) and then it is aseptically spray-dried. The powder obtained is aseptically filled into sterile depyrogenized vials in a laminar flow box of A class purity.

Example 4

Preparation of Lyophilized Injection Form of Platinum Complex LA-12

Platinum complex LA-12 (1 part by weight) is suspended in water for injections (40 parts by weight) whereupon HP-beta-cyclodextrin (3 parts by weight) is gradually added to this suspension under constant stirring, and stirring is continued until the formed inclusion complex completely dissolves. Then, the obtained solution is sterilized by membrane filtration (membrane pore size 0.22 μm) whereupon the sterile solution is filled into vials and is subjected to lyophilization.

Example 5

Preparation of Dry Injection Form of Platinum Complex LA-12

Platinum complex LA-12 (1 part by weight) is suspended in water for injections (40 parts by weight). HP-beta-Cyclodextrin (3 parts by weight) is then added to the obtained suspension under constant stirring, and stirring is continued until the formed inclusion complex completely dissolves. The obtained solution is then sterilized by membrane filtration (membrane pore size 0.22 μm) whereupon it is aseptically spray dried. The obtained powder is then aseptically filled into sterile depyrogenized vials in a laminar flow box of A class purity.

Claims

1. A pharmaceutical composition for administration by injection, characterized in that it consists of a mixture of a platinum complex of general formula I

2. The pharmaceutical composition according to claim 1, characterized in that it contains at least one cyclodextrin and/or at least one cyclodextrin derivative and platinum complex of general formula I in a weight ratio 0,1:1 to 1:10, preferably 1:1 to 1:8.

3. The pharmaceutical composition according to claim 1, characterized in that the aqueous medium is water or an aqueous buffer, pH 4 to 8, preferably 4.